Blueprint Medicines Corporation (0HOJ.L)
USD 85.0
(-2.48%)
USD 85.0
(-2.48%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 21.22 Million USD | -28.53% |
| 2022 | 29.69 Million USD | 36.12% |
| 2021 | 21.81 Million USD | 154.25% |
| 2020 | 8.58 Million USD | 101.98% |
| 2019 | -434.02 Million USD | -43402200100.0% |
| 2018 | 1.00 USD | 0.0% |
| 2017 | - USD | 100.0% |
| 2016 | -54.05 Million USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q3 | 12.52 Million USD | -15.29% |
| 2024 Q1 | 30.94 Million USD | 45.79% |
| 2024 Q2 | 14.78 Million USD | -52.2% |
| 2023 Q4 | 21.22 Million USD | 28.96% |
| 2023 Q1 | 17.52 Million USD | -41.0% |
| 2023 FY | 21.22 Million USD | -28.53% |
| 2023 Q2 | 17.01 Million USD | -2.88% |
| 2023 Q3 | 16.45 Million USD | -3.29% |
| 2022 FY | 29.69 Million USD | 36.12% |
| 2022 Q4 | 29.69 Million USD | -15.76% |
| 2022 Q3 | 35.25 Million USD | -0.57% |
| 2022 Q2 | 35.45 Million USD | 17.61% |
| 2022 Q1 | 30.14 Million USD | 38.17% |
| 2021 FY | 21.81 Million USD | 154.25% |
| 2021 Q3 | 16.57 Million USD | 8.93% |
| 2021 Q4 | 21.81 Million USD | 31.67% |
| 2021 Q1 | 16.03 Million USD | 86.81% |
| 2021 Q2 | 15.21 Million USD | -5.11% |
| 2020 Q2 | 4.35 Million USD | 63.56% |
| 2020 Q3 | 5.56 Million USD | 27.67% |
| 2020 FY | 8.58 Million USD | 101.98% |
| 2020 Q4 | 8.58 Million USD | 54.2% |
| 2020 Q1 | 2.66 Million USD | 104.14% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q1 | - USD | -100.0% |
| 2019 Q4 | -64.4 Million USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 FY | -434.02 Million USD | -43402200100.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 FY | 1.00 USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q4 | 1.00 USD | 0.0% |
| 2017 Q3 | - USD | -100.0% |
| 2017 Q2 | 1.00 USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 FY | - USD | 100.0% |
| 2017 Q1 | - USD | 100.0% |
| 2016 Q3 | 1.00 USD | 0.0% |
| 2016 FY | -54.05 Million USD | 0.0% |
| 2016 Q4 | -54.05 Million USD | -5405900100.0% |
| 2016 Q2 | - USD | -100.0% |
| 2016 Q1 | 1.00 USD | 0.0% |
| 2015 Q1 | 1.00 USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q2 | - USD | -100.0% |
| 2015 Q3 | 1.00 USD | 0.0% |
| 2015 Q4 | - USD | -100.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| uniQure N.V. | 12.02 Million USD | -76.505% |
| Agios Pharmaceuticals, Inc. | 19.07 Million USD | -11.255% |
| Amicus Therapeutics, Inc. | 59.69 Million USD | 64.448% |
| Atara Biotherapeutics, Inc. | 9.7 Million USD | -118.659% |
| bluebird bio, Inc. | 22.91 Million USD | 7.4% |
| Cara Therapeutics, Inc. | 2.82 Million USD | -652.322% |
| Imunon, Inc. | - USD | -Infinity% |
| Editas Medicine, Inc. | - USD | -Infinity% |
| IQVIA Holdings Inc. | - USD | -Infinity% |
| Mettler-Toledo International Inc. | 385.86 Million USD | 94.5% |
| Myriad Genetics, Inc. | 20.1 Million USD | -5.587% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | 44.587% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 72.583% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 99.745% |
| Waters Corporation | 516.23 Million USD | 95.889% |
| Thermo Fisher Scientific Inc. | 5.08 Billion USD | 99.583% |
| Biogen Inc. | 2.52 Billion USD | 99.16% |
| Nektar Therapeutics | 16.1 Million USD | -31.812% |
| Perrigo Company plc | 1.14 Billion USD | 98.14% |
| Dynavax Technologies Corporation | 53.29 Million USD | 60.175% |
| Illumina, Inc. | 587 Million USD | 96.384% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Iovance Biotherapeutics, Inc. | 10.37 Million USD | -104.618% |
| Heron Therapeutics, Inc. | 42.11 Million USD | 49.601% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 98.083% |
| Sangamo Therapeutics, Inc. | - USD | -Infinity% |
| Evolus, Inc. | 10.99 Million USD | -92.971% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Aclaris Therapeutics, Inc. | - USD | -Infinity% |
| Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 99.178% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | 67.659% |
| FibroGen, Inc. | 41.56 Million USD | 48.94% |
| Agilent Technologies, Inc. | 1.03 Billion USD | 97.942% |
| OPKO Health, Inc. | 65.69 Million USD | 67.696% |
| Homology Medicines, Inc. | - USD | -Infinity% |
| Geron Corporation | - USD | -Infinity% |
| Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | 76.193% |
| Exelixis, Inc. | 17.32 Million USD | -22.513% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | - USD | -Infinity% |
| Zoetis Inc. | 2.56 Billion USD | 99.172% |
| Axsome Therapeutics, Inc. | 15.13 Million USD | -40.225% |
| Abeona Therapeutics Inc. | -2.44 Million USD | 968.372% |
| Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 97.127% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 28.42 Million USD | 25.337% |
| Sarepta Therapeutics, Inc. | 322.85 Million USD | 93.427% |
| Corcept Therapeutics Incorporated | 7.73 Million USD | -174.554% |
| Halozyme Therapeutics, Inc. | 127.6 Million USD | 83.368% |
| Insmed Incorporated | 83.24 Million USD | 74.506% |
| TG Therapeutics, Inc. | 39.82 Million USD | 46.707% |
| Incyte Corporation | 62.97 Million USD | 66.298% |
| Emergent BioSolutions Inc. | 328.9 Million USD | 93.547% |